A phase II GETNE-DUTHY study is advancing a new combination approach for advanced thyroid cancer using checkpoint blockade with durvalumab and tremelimumab. The trial is led by Capdevila, Hernando, and Molina-Cerillo, and evaluates whether the dual PD-(L)1 and CTLA-4 strategy can improve outcomes in a setting with limited durable options. Separately, researchers reported preclinical/clinical immunotherapy modulation tied to colorectal cancer, where circulating glycocholic acid (GCA) appears to influence response to immune checkpoint therapy. The work frames GCA as a potential biomarker or combination lever for improving immunotherapy efficacy. Together, the updates underscore a continuing focus on refining checkpoint inhibitor combinations and identifying actionable biology that could widen the proportion of patients who respond.